Stapokibart for seasonal allergy relief
Treatments studied
Part of Ear, nose & throat, Immune system & allergy clinical trials.
This study looks at how well an allergy injection called Stapokibart works for people with seasonal allergic rhinitis (hay fever). If you qualify, you'll receive the treatment as part of your normal care, and the study team will track your results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your doctor must have already decided to use Stapokibart for your seasonal allergies as part of your regular care.
- You cannot have a known allergy to Stapokibart.
- You cannot be in another clinical trial or planning to join one while in this study.
- You cannot have a blood cancer (hematologic malignancy).
- You cannot be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new nasal spray designed to relieve the stuffy nose, sneezing, and itching caused by seasonal allergies. It is for people with moderate to severe symptoms that aren’t controlled by other treatments.
This study tests an injectable medication called Stapokibart for teenagers with seasonal allergies (hay fever). It aims to see if the drug can reduce allergy symptoms like sneezing, runny nose, and itchy eyes.
This trial tests a new biologic medicine (injection) to see if it can better control seasonal allergy symptoms in teens who haven't had good relief from standard treatments like nasal sprays.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
This trial tests a new injection called Stapokibart to see if it can help people with moderate to severe bullous pemphigoid, a skin condition that causes painful blisters. The treatment aims to reduce blistering and itching.
Hear when a new SAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.